Brown Brothers Harriman & CO Maxcyte, Inc. Transaction History
Brown Brothers Harriman & CO
- $13.6 Billion
- Q4 2024
A detailed history of Brown Brothers Harriman & CO transactions in Maxcyte, Inc. stock. As of the latest transaction made, Brown Brothers Harriman & CO holds 6,255 shares of MXCT stock, worth $26,083. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,255
Previous 6,255
-0.0%
Holding current value
$26,083
Previous $24,000
8.33%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding MXCT
# of Institutions
125Shares Held
70.3MCall Options Held
1KPut Options Held
2K-
Cadian Capital Management, LP New York, NY9.34MShares$39 Million2.26% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$34 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.43MShares$22.6 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$21 Million18.06% of portfolio
-
Morgan Stanley New York, NY4.41MShares$18.4 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $424M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...